Stock SOT SOCIETE DE THERAPEUTIQUE MAROCAINE S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Societe de Therapeutique Marocaine S.A.

Equities

SOT

MA0000012502

Pharmaceuticals

End-of-day quote Casablanca S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
1,010 MAD 0.00% Intraday chart for Societe de Therapeutique Marocaine S.A. -0.10% +6.20%
Apr. 19 Société de Therapeutique Marocaine S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Societe de Therapeutique Marocaine S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2023 2024
Capitalization 1 2,950 2,918 3,600 7,272 7,272
Enterprise Value (EV) 1 3,117 2,918 3,889 6,847 7,272
P/E ratio 13.6 x 13.6 x 15.6 x 26.1 x 22 x
Yield 4.09% - 1.05% - -
Capitalization / Revenue 1,854,305 x - 1,989,042 x - -
EV / Revenue 1,854,306 x - 1,989,042 x - -
EV / EBITDA 10,803,428 x - 9,799,863 x - -
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book 3.7 x - 4.25 x - -
Nbr of stocks (in thousands) 7,200 7,200 7,200 7,200 7,200
Reference price 2 409.8 405.2 500.0 1,010 1,010
Announcement Date 3/23/19 5/1/21 4/30/21 4/19/24 -
1MAD in Million2MAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2023 2024
Net sales 1,591 - 1,810 - -
EBITDA 273.1 - 367.4 - -
EBIT 266 - 366 - -
Operating Margin 16.72% - 20.22% - -
Earnings before Tax (EBT) - - - - -
Net income 217 - 238.2 - -
Net margin 13.64% - 13.16% - -
EPS 1 30.19 29.77 32.00 36.50 46.00
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share 16.75 - 5.250 - -
Announcement Date 3/23/19 5/1/21 4/30/21 4/19/24 -
1MAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 198 194 155 289 136 302
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 0.8418 x 0.7103 x - 0.6725 x 0.2657 x 0.5649 x
Free Cash Flow 1 46.8 57.4 102 40.2 339 67.6
ROE (net income / shareholders' equity) 22.9% 29.4% 25.4% 20.6% 22.3% 19.6%
ROA (Net income/ Total Assets) 11.3% 12.3% 13.6% 12.5% 13.8% 13.1%
Assets 1 1,325 1,766 1,571 1,835 2,014 2,032
Book Value Per Share 2 94.70 - 124.0 163.0 180.0 197.0
Cash Flow per Share 2 0.8500 - 4.240 3.570 12.20 6.240
Capex 1 59.6 48.3 31.4 59.2 62.6 70.1
Capex / Sales 4.21% 3.04% 1.84% 3.29% 3.04% 3.05%
Announcement Date 4/9/18 2/4/21 2/4/21 5/1/21 4/15/22 4/29/23
1MAD in Million2MAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1,010
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SOCIETE DE THERAPEUTIQUE MAROCAINE S.A. Stock Societe de Therapeutique Marocaine S.A.
+6.20% 717M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SOT Stock
  4. Financials Societe de Therapeutique Marocaine S.A.